![Michael Atkins](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Atkins
Direttore/Membro del Consiglio presso WEREWOLF THERAPEUTICS, INC.
Patrimonio netto: 74 546 $ in data 31/05/2024
Profilo
Michael B.
Atkins is currently the Director at the Melanoma Research Foundation.
He is also an Independent Director at Werewolf Therapeutics, Inc. starting in 2024.
Additionally, he holds the position of President at the Society For Immunotherapy of Cancer.
In 2002, he started working as a Professor at Harvard Medical School.
Dr. Atkins completed his undergraduate degree at Tufts University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
24/05/2024 | 14 419 ( 0.03% ) | 74 546 $ | 31/05/2024 |
Posizioni attive di Michael Atkins
Società | Posizione | Inizio |
---|---|---|
WEREWOLF THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 04/01/2024 |
Melanoma Research Foundation
![]() Melanoma Research Foundation Miscellaneous Commercial ServicesCommercial Services Melanoma Research Foundation engages in finding treatments and cure for melanoma through research. It also educates patients, caregivers, and physicians about the prevention and diagnosis of melanoma. The company was founded by Diana Ashby in 1996 and is headquartered in Washington, DC. | Direttore/Membro del Consiglio | - |
Harvard Medical School | Corporate Officer/Principal | 01/01/2002 |
Society For Immunotherapy of Cancer
![]() Society For Immunotherapy of Cancer Miscellaneous Commercial ServicesCommercial Services The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. | Presidente | - |
Formazione di Michael Atkins
Tufts University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
WEREWOLF THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Melanoma Research Foundation
![]() Melanoma Research Foundation Miscellaneous Commercial ServicesCommercial Services Melanoma Research Foundation engages in finding treatments and cure for melanoma through research. It also educates patients, caregivers, and physicians about the prevention and diagnosis of melanoma. The company was founded by Diana Ashby in 1996 and is headquartered in Washington, DC. | Commercial Services |
Society For Immunotherapy of Cancer
![]() Society For Immunotherapy of Cancer Miscellaneous Commercial ServicesCommercial Services The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. | Commercial Services |
- Borsa valori
- Insiders
- Michael Atkins